Please login to the form below

Not currently logged in
Email:
Password:

Biotest makes two senior management appointments

Promotion for Jörg Schüttrumpf while Markus Rothenburger joins from Fresenius Kabi

Markus Rothenburger, Biotest Biotest has promoted Dr Jörg Schüttrumpf to head its global research efforts, while Professor Markus Rothenburger (pictured) will join the company as head of medical/regulatory affairs.

Dr Schüttrumpf only joined the Germany-based biopharma in July 2012, and will now have responsibility for early research and development in Biotest's key areas of focus: immunology, haematology and intensive care.

His career prior to joining Biotest includes positions at Essen und Frankfurt am Main university hospitals as well as at the blood donor service DRK-Blutspendedienst Baden-Württemberg-Hessen.

“He is the ideal candidate to head this important area,” said Biotest's chair Professor Gregor Schulz.

“Dr Schüttrumpf is a specialist in the fields of coagulation research and transfusion medicine, and was therefore our first choice for this position.'

Prof Rothenburger joins Biotest from his role as VP medical and clinical affairs at Fresenius Kabi.

He has also served at Novartis, and has clinical experience in vascular and heart surgery during his time working in hospital.

“We win an excellent medical specialist and a pharmaceutical manager with wide-ranging industry connections,” said Prof Schulz .

19th December 2012

Share

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....